Overview

* Exagen Q2 2025 revenue grows 14% yr/yr, beating analyst expectations

* Company reports Q2 net loss of $4.4 mln despite revenue growth

* Exagen ( XGN ) strengthens balance sheet with $20.2 mln public offering and loan facility

Outlook

* Exagen ( XGN ) expects 2025 full-year revenue between $65 mln and $70 mln

* Company anticipates positive adjusted EBITDA in Q4 at high end of FY revenue forecast

Result Drivers

* TEST VOLUME INCREASE - AVISE CTD test volume grew 14% compared to Q1 2025, contributing to revenue growth

* HIGHER ASP - Trailing twelve-month average selling price for AVISE CTD tests increased by $27 over Q2 2024

* BALANCE SHEET STRENGTHENING - Co closed $20.2 mln public offering and new loan facility, boosting cash reserves

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $17.20 $16.30

Revenue mln mln (6

Analysts

)

Q2 EPS -$0.21

Q2 Net -$4.44

Income mln

Q2 $13.02

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Exagen Inc ( XGN ) is $8.50, about 13.1% above its July 28 closing price of $7.39

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)